Abstract
Background: Hyperhomocysteinemia has been associated with cognitive dysfunction and dementia. The incidence of dementia in Parkinsons Disease (PD) patients is higher than in the general population and plasma Homocysteine concentrations are increased in L-dopa treated PD patients. Objective: We evaluated the possible correlations between L-Dopa related hyperhomocysteinemia and cognitive dysfunction in PD. Methods: A Medline literature search was performed to identify all published studies on Homocysteine and cognitive dysfunction and dementia during the course of PD from 1966 to 31/03/2010. Results: Sixteen studies were found for review; ten studies focused on homocysteine and cognitive dysfunction in PD patients, five on homocysteine and PD dementia and two on homocysteine and markers of neurodegeneration in PD. The design of the study was retrospective in 14 studies, while 2 had a prospective design, with a variable follow-up period (from 24-weeks to 2 years). In most of the studies plasma homocysteine levels significantly correlated with cognitive functions, dementia and markers of neurodegeneration in PD patients. However, some studies did not confirm these findings. Several factors may concur to explain these partially conflicting results, including the retrospective design of the studies, their small sample size, their high percentage of excluded patients, and the use of a wide range of neuropsychological tasks in assessment of cognitive dysfunctions across the available studies. Conclusions: Available data seem to indicate a potential role of L-dopa related hyperhomocysteinemia on cognitive impairment and dementia during the course of PD.
Keywords: Parkinson's disease, Dementia, homocysteine, L-dopa, cognitive dysfunctions
Current Medicinal Chemistry
Title: Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Volume: 17 Issue: 28
Author(s): S. Zoccolella, S. V. Lamberti, G. Iliceto, A. Santamato, P. Lamberti and G. Logroscino
Affiliation:
Keywords: Parkinson's disease, Dementia, homocysteine, L-dopa, cognitive dysfunctions
Abstract: Background: Hyperhomocysteinemia has been associated with cognitive dysfunction and dementia. The incidence of dementia in Parkinsons Disease (PD) patients is higher than in the general population and plasma Homocysteine concentrations are increased in L-dopa treated PD patients. Objective: We evaluated the possible correlations between L-Dopa related hyperhomocysteinemia and cognitive dysfunction in PD. Methods: A Medline literature search was performed to identify all published studies on Homocysteine and cognitive dysfunction and dementia during the course of PD from 1966 to 31/03/2010. Results: Sixteen studies were found for review; ten studies focused on homocysteine and cognitive dysfunction in PD patients, five on homocysteine and PD dementia and two on homocysteine and markers of neurodegeneration in PD. The design of the study was retrospective in 14 studies, while 2 had a prospective design, with a variable follow-up period (from 24-weeks to 2 years). In most of the studies plasma homocysteine levels significantly correlated with cognitive functions, dementia and markers of neurodegeneration in PD patients. However, some studies did not confirm these findings. Several factors may concur to explain these partially conflicting results, including the retrospective design of the studies, their small sample size, their high percentage of excluded patients, and the use of a wide range of neuropsychological tasks in assessment of cognitive dysfunctions across the available studies. Conclusions: Available data seem to indicate a potential role of L-dopa related hyperhomocysteinemia on cognitive impairment and dementia during the course of PD.
Export Options
About this article
Cite this article as:
Zoccolella S., Lamberti V. S., Iliceto G., Santamato A., Lamberti P. and Logroscino G., Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?, Current Medicinal Chemistry 2010; 17 (28) . https://dx.doi.org/10.2174/092986710792232012
DOI https://dx.doi.org/10.2174/092986710792232012 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroimaging Correlates of 22q11.2 Deletion Syndrome: Implications for Schizophrenia Research
Current Topics in Medicinal Chemistry Editorial
Current Medical Imaging 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research Overview and Findings from the Religious Orders Study
Current Alzheimer Research Understanding the Obstacles to Uptake of Intervention Programmes and Services for Persons with Dementia
Current Alzheimer Research The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer’s Disease
Current Alzheimer Research Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets The Blood-Brain Barrier in NeuroAIDS
Current HIV Research Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study
Current Alzheimer Research Effects of ACE Inhibitors on Skeletal Muscle
Current Pharmaceutical Design Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets The Hypothesis of the Catalytic Action of Nucleic Acid on the Conversion of Prion Protein
Protein & Peptide Letters Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research Perspectives in Medicinal Chemistry: Focusing on the Link between Diabetes, Alzheimer's Disease and Cancer for the Discovery of New Medicines
Current Topics in Medicinal Chemistry